All In Biotech

Drug Trial Radar · NCT04991116

Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis

An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis.

Last checked: Nov 19, 2026Latest source record: Mar 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

529

Actual

Start

Jun 30, 2022

Primary completion

Dec 2028

Study completion Apr 2029

Sponsor

Sponsor type
Industry
First posted
Aug 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open label phase 3 study

Conditions

  • Psoriatic Arthritis

Interventions

  • TILD sub-cutaneous (SC) injectionDrug

    1 mL injection of study medication

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and intensity of Adverse Events (AEs) recorded through the study periodTime frame: Week 124
  2. Proportion of Subject Who Reached (American College of Rheumatology Score of 20) ACR20Time frame: Week 124
  3. Proportion of Subjects Who Reached (American College of Rheumatology Score of 50) ACR50Time frame: Week 124
  4. Proportion of Subjects Who Reached (American College of Rheumatology Score of 70) ACR70Time frame: Week 124

Locations

99 sites in 14 countries. Site status is shown where the registry gives one.

  • Sunpharma site no 50

    Dothan, Alabama

  • Sunpharma site no 80

    Gilbert, Arizona

  • Sunpharma site no 65

    Mesa, Arizona

  • Sunpharma site no 105

    Phoenix, Arizona

  • Sunpharma site no. 30

    Covina, California

  • Sunpharma site no 110

    Encino, California

  • Sunpharma site no. 17

    Fountain Valley, California

  • Sunpharma site no. 15

    Thousand Oaks, California

  • Sunpharma site no 113

    Avon Park, Florida

  • Sunpharma site no. 21

    Clearwater, Florida

  • Sunpharma site no. 02

    Hialeah, Florida

  • Sunpharma site no 71

    Kissimmee, Florida

  • Sunpharma site no 107

    Margate, Florida

  • Sunpharma site no. 05

    New Port Richey, Florida

  • Sunpharma site no 32

    Ocoee, Florida

  • SunPharma Site no 22

    Tamarac, Florida

  • Sunpharma site no 52

    Gainesville, Georgia

  • Sunpharma site no 51

    Orland Park, Illinois

  • Sunpharma site no 49

    Schaumburg, Illinois

  • Sunpharma site no 47

    Skokie, Illinois

  • Sunpharma site no. 20

    Wichita, Kansas

  • Sunpharma site no. 14

    Springfield, Missouri

  • Sunpharma site no 104

    St Louis, Missouri

  • Sunpharma site no 48

    Kalispell, Montana

  • Sunpharma Site no 27

    Lincoln, Nebraska

  • Sunpharma site no 33

    Voorhees Township, New Jersey

  • Sunpharma site no 34

    Charlotte, North Carolina

  • Sunpharma site no 111

    Leland, North Carolina

  • Sunpharma site no 53

    Wilmington, North Carolina

  • Sunpharma site no 35

    Minot, North Dakota

  • Sunpharma site no. 11

    Middleburg Heights, Ohio

  • Sunpharma site no 31

    Greenville, South Carolina

  • Sunpharma site no. 08

    Baytown, Texas

  • Sunpharma site no. 13

    Baytown, Texas

  • Sunpharma Site no 28

    Lubbock, Texas

  • Sunpharma site no 109

    Mesquite, Texas

  • Sunpharma site no. 03

    San Antonio, Texas

  • Sunpharma site no. 16

    San Antonio, Texas

  • Sunpharma site no. 01

    Tomball, Texas

  • Sunpharma site no 96

    Salt Lake City, Utah

Showing 40 of 99 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.